Great news in hep C treatment, EPCLUSA the first pangenotypic approved in Quebec


After a long waiting for, and hard discussions about pricing, we are now pleased to have the first pangenotypic (for all genotypes) approved in Quebec.

This access to treatments is now expanded to a broader population of hepatitis C patients in our province.

Without ribavirine for genotypes 2 et 3, one pill for 12 weeks (24 weeks for patient with decompensated cirrhosis), no bad side effects (headache and fatigue).

We definitively are on the track for hep C elimination….

Laurence Mersilian

EPCLUSA™, to treat all six genotypes of chronic hepatitis C infection, added to the Liste des médicaments de la RAMQ (CNW Group/Gilead Sciences, Inc.)